Quarterly report · Q3
4483.TEDINET S100Q8QG
Period2022-04-01 → 2022-12-31
Filed2023-02-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥19.5bn | 2022-04-01 → 2022-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥7.5bn | 2022-10-01 → 2022-12-31d | Cons. | Revenue IFRS |
| Revenue | ¥21.8bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥15.7bn | 2021-04-01 → 2021-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥6.1bn | 2021-10-01 → 2021-12-31d | Cons. | Revenue IFRS |
| Operating income | ¥4.0bn | 2022-04-01 → 2022-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.8bn | 2022-10-01 → 2022-12-31d | Cons. | Operating profit loss IFRS |
| Operating income | ¥3.4bn | 2021-04-01 → 2021-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.7bn | 2021-10-01 → 2021-12-31d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥4.0bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥1.8bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥4.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥3.4bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥1.7bn | 2021-10-01 → 2021-12-31d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥2.7bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥1.2bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥3.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥2.3bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥1.1bn | 2021-10-01 → 2021-12-31d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥2.7bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥1.2bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss IFRS |
| Net income | ¥2.3bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥1.1bn | 2021-10-01 → 2021-12-31d | Cons. | Profit loss IFRS |
| Total assets | ¥95.1bn | at 2022-12-31 | Cons. | Assets IFRS |
| Total assets | ¥62.1bn | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥60.4bn | at 2021-12-31 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥32.3bn | at 2022-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥30.9bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥62.9bn | at 2022-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥31.2bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥30.1bn | at 2021-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥28.3bn | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥62.9bn | at 2022-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥31.2bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥30.1bn | at 2021-12-31 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥21.8bn | at 2022-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥13.2bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥14.5bn | at 2021-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥19.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥2.5bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥3.8bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥1.9bn | 2021-04-01 → 2021-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥21.8bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥8.1bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥5.3bn | 2021-04-01 → 2021-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥27.9bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥2.4bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥2.1bn | 2021-04-01 → 2021-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥44.98 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥19.28 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥57.74 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥40.46 | 2021-04-01 → 2021-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥20.16 | 2021-10-01 → 2021-12-31d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥42.66 | 2022-04-01 → 2022-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥18.45 | 2022-10-01 → 2022-12-31d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥54.16 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥38.14 | 2021-04-01 → 2021-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥18.99 | 2021-10-01 → 2021-12-31d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 66.1% | at 2022-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 50.2% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 49.9% | at 2021-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 72
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥189m |
| Reconciling Itemsreconciling | revenue | 2022-10-01 → 2022-12-31 | −¥62m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥189m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-10-01 → 2022-12-31 | −¥62m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥417m |
| Reconciling Itemsreconciling | segment profit | 2022-10-01 → 2022-12-31 | −¥227m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥2.8bn |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2022-10-01 → 2022-12-31 | ¥944m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥2.7bn |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2022-10-01 → 2022-12-31 | ¥901m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥127m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2022-10-01 → 2022-12-31 | ¥43m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥310m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2022-10-01 → 2022-12-31 | ¥118m |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥13.1bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue | 2022-10-01 → 2022-12-31 | ¥5.2bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥13.1bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue external | 2022-10-01 → 2022-12-31 | ¥5.2bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥62m |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2022-10-01 → 2022-12-31 | ¥19m |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥4.0bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | segment profit | 2022-10-01 → 2022-12-31 | ¥2.0bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥3.8bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue | 2022-10-01 → 2022-12-31 | ¥1.4bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥3.8bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue external | 2022-10-01 → 2022-12-31 | ¥1.4bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.4bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | segment profit | 2022-10-01 → 2022-12-31 | ¥492m |
| —segment total | revenue | 2022-04-01 → 2022-12-31 | ¥19.7bn |
| —segment total | revenue | 2022-10-01 → 2022-12-31 | ¥7.5bn |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥19.5bn |
| —segment total | revenue external | 2022-10-01 → 2022-12-31 | ¥7.5bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥189m |
| —segment total | revenue intersegment | 2022-10-01 → 2022-12-31 | ¥62m |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | ¥5.7bn |
| —segment total | segment profit | 2022-10-01 → 2022-12-31 | ¥2.6bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-12-31 | −¥143m |
| Reconciling Itemsreconciling | revenue | 2021-10-01 → 2021-12-31 | −¥54m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-12-31 | −¥143m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-10-01 → 2021-12-31 | −¥54m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-12-31 | −¥242m |
| Reconciling Itemsreconciling | segment profit | 2021-10-01 → 2021-12-31 | −¥85m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥2.6bn |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2021-10-01 → 2021-12-31 | ¥907m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥2.5bn |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2021-10-01 → 2021-12-31 | ¥873m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥90m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2021-10-01 → 2021-12-31 | ¥34m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥209m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2021-10-01 → 2021-12-31 | ¥46m |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥9.9bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue | 2021-10-01 → 2021-12-31 | ¥4.1bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥9.8bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue external | 2021-10-01 → 2021-12-31 | ¥4.0bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥52m |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2021-10-01 → 2021-12-31 | ¥20m |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥3.4bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | segment profit | 2021-10-01 → 2021-12-31 | ¥1.7bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥3.4bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue | 2021-10-01 → 2021-12-31 | ¥1.2bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥3.4bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue external | 2021-10-01 → 2021-12-31 | ¥1.2bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥1.2bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | segment profit | 2021-10-01 → 2021-12-31 | ¥470m |
| —segment total | revenue | 2021-04-01 → 2021-12-31 | ¥15.8bn |
| —segment total | revenue | 2021-10-01 → 2021-12-31 | ¥6.2bn |
| —segment total | revenue external | 2021-04-01 → 2021-12-31 | ¥15.7bn |
| —segment total | revenue external | 2021-10-01 → 2021-12-31 | ¥6.1bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥143m |
| —segment total | revenue intersegment | 2021-10-01 → 2021-12-31 | ¥54m |
| —segment total | segment profit | 2021-04-01 → 2021-12-31 | ¥4.8bn |
| —segment total | segment profit | 2021-10-01 → 2021-12-31 | ¥2.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 842
| Item | Context | Value | Unit |
|---|---|---|---|
| Equity IFRS | CurrentQuarterInstant_EquityAttributableToOwnersOfParentIFRSMember | 62877000000 | JPY |
| Equity IFRS | CurrentQuarterInstant_NonControllingInterestsIFRSMember | -19000000 | JPY |
| Equity IFRS | CurrentQuarterInstant | 62857000000 | JPY |
| Profit loss before tax IFRS | Prior1YTDDuration | 3396000000 | JPY |
| Profit loss before tax IFRS | CurrentYTDDuration | 4007000000 | JPY |
| Depreciation and amortization ope cf IFRS | Prior1YTDDuration | 1191000000 | JPY |
| Depreciation and amortization ope cf IFRS | CurrentYTDDuration | 1487000000 | JPY |
| Decrease increase in trade and other receivables ope cf IFRS | Prior1YTDDuration | -740000000 | JPY |
| Decrease increase in trade and other receivables ope cf IFRS | CurrentYTDDuration | -588000000 | JPY |
| Decrease increase in inventories ope cf IFRS | Prior1YTDDuration | -42000000 | JPY |
| Decrease increase in inventories ope cf IFRS | CurrentYTDDuration | -58000000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | Prior1YTDDuration | -31000000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | CurrentYTDDuration | -424000000 | JPY |
| Other changes in working capital ope cf IFRS | Prior1YTDDuration | -550000000 | JPY |
| Other changes in working capital ope cf IFRS | CurrentYTDDuration | -45000000 | JPY |
| Subtotal ope cf IFRS | Prior1YTDDuration | 3222000000 | JPY |
| Subtotal ope cf IFRS | CurrentYTDDuration | 4378000000 | JPY |
| Interest and dividends received ope cf IFRS | Prior1YTDDuration | 36000000 | JPY |
| Interest and dividends received ope cf IFRS | CurrentYTDDuration | 0 | JPY |
| Interest paid ope cf IFRS | Prior1YTDDuration | -43000000 | JPY |
| Interest paid ope cf IFRS | CurrentYTDDuration | -68000000 | JPY |
| Income taxes refund paid ope cf IFRS | Prior1YTDDuration | -1332000000 | JPY |
| Income taxes refund paid ope cf IFRS | CurrentYTDDuration | -1818000000 | JPY |
| Net cash provided by used in operating activities IFRS | Prior1YTDDuration | 1883000000 | JPY |
| Net cash provided by used in operating activities IFRS | CurrentYTDDuration | 2490000000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | Prior1YTDDuration | -258000000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | CurrentYTDDuration | -1192000000 | JPY |
| Purchase of intangible assets inv cf IFRS | Prior1YTDDuration | -597000000 | JPY |
| Purchase of intangible assets inv cf IFRS | CurrentYTDDuration | -802000000 | JPY |
| Payments for loans receivable inv cf IFRS | Prior1YTDDuration | -10000000 | JPY |
| Payments for loans receivable inv cf IFRS | CurrentYTDDuration | -760000000 | JPY |
| Collection of loans receivable inv cf IFRS | Prior1YTDDuration | － | JPY |
| Collection of loans receivable inv cf IFRS | CurrentYTDDuration | 110000000 | JPY |
| Purchase of investments inv cf IFRS | Prior1YTDDuration | -53000000 | JPY |
| Purchase of investments inv cf IFRS | CurrentYTDDuration | -166000000 | JPY |
| Increase due to acquisition of consolidated subsidiaries inv cf IFRS | Prior1YTDDuration | － | JPY |
| Increase due to acquisition of consolidated subsidiaries inv cf IFRS | CurrentYTDDuration | 25000000 | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | Prior1YTDDuration | -4327000000 | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | CurrentYTDDuration | -19213000000 | JPY |
| Other inv cf IFRS | Prior1YTDDuration | -21000000 | JPY |
| Other inv cf IFRS | CurrentYTDDuration | 195000000 | JPY |
| Net cash provided by used in investing activities IFRS | Prior1YTDDuration | -5268000000 | JPY |
| Net cash provided by used in investing activities IFRS | CurrentYTDDuration | -21803000000 | JPY |
| Proceeds from short term borrowings fin cf IFRS | Prior1YTDDuration | － | JPY |
| Proceeds from short term borrowings fin cf IFRS | CurrentYTDDuration | 19330000000 | JPY |
| Repayments of short term borrowings fin cf IFRS | Prior1YTDDuration | -2622000000 | JPY |
| Repayments of short term borrowings fin cf IFRS | CurrentYTDDuration | -19543000000 | JPY |
| Proceeds from long term borrowings fin cf IFRS | Prior1YTDDuration | 1470000000 | JPY |
| Proceeds from long term borrowings fin cf IFRS | CurrentYTDDuration | 961000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | Prior1YTDDuration | -590000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |